SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Moskowitz C. An update on the management of relapsed and primary refractory Hodgkin's disease. Semin Oncol. 2004; 31( 2 suppl 4): 5459.
  • 2
    Hasenclever D,Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998; 339: 15061514.
  • 3
    Jemal A,Murray T,Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 1030.
  • 4
    Longo DL,Duffey PL,Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992; 10: 210218.
  • 5
    Santaro A,Bonfante V,Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med. 1982; 96: 139143.
  • 6
    Yahalom J,Gulati S. Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation. Ann Oncol. 1991; 2( suppl 2): 6771.
  • 7
    Crump M,Smith AM,Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol. 1993; 11: 704711.
  • 8
    Linch DC,Winfield D,Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993; 341: 10511054.
  • 9
    Yuen AR,Rosenberg SA,Hoppe RT,Halpern JD,Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood. 1997; 89: 814822.
  • 10
    Josting A,Katay I,Rueffer U, et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Ann Oncol. 1998; 9: 289295.
  • 11
    Nademanee A,O'Donnell MR,Snyder DS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood. 1995; 85: 13811390.
  • 12
    Horning SJ,Chao NJ,Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood. 1997; 89: 801813.
  • 13
    Sweetenham JW,Taghipour G,Milligan D, et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997; 20: 745752.
  • 14
    Schmitz N,Pfistner B,Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002; 359: 20652071.
  • 15
    Voillant L,Deconinck E,Flesch M, et al. Role of chemoresistance prior to autologous bone marrow transplantation for Hodgkin's disease. Nouv Rev Fr Hematol. 1994; 36: 423430.
  • 16
    Argiris A,Seropian S,Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol. 2000; 11: 665672.
  • 17
    Sureda A,Arranz R,Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol. 2001; 19: 13951404.
  • 18
    Czyz J,Dziadziuszko R,Knopinska-Postuszuy W, et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol. 2004; 15: 12221230.
  • 19
    Sureda A,Constans M,Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005; 16: 625633.
  • 20
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 21
    Bartlett NL,Niedzwiecki D,Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007; 18: 10711079.
  • 22
    Santoro A,Bredenfeld H,Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000; 18: 26152619.
  • 23
    Zhang M,Yao Z,Zhang Z, et al. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood. 2006; 108: 705710.
  • 24
    Anderlini P,Saliba R,Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005; 35: 943951.
  • 25
    Peggs KS,Hunter A,Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005; 365: 19341941.
  • 26
    Alvarez I,Sureda A,Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006; 12: 172183.
  • 27
    Brice P,Divine M,Simon D, et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Ann Oncol. 1999; 10: 14851488.
  • 28
    Bartlett NL,Younes A,Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008; 111: 18481854.
  • 29
    Gopal AK,Gooley TA,Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003; 102: 23512357.
  • 30
    Nademanee A,Forman S,Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. 2005; 106: 28962902.
  • 31
    Vose JM,Bierman PJ,Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 461467.
  • 32
    Schnell R,Dietlein M,Staak JO, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol. 2005; 23: 46694678.
  • 33
    Svoboda J,Andreadis C,Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2006; 38: 211216.
  • 34
    Spaepen K,Stroobants S,Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003; 102: 5359.